Status: Recruiting
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Participants needed: 170
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Recursion Pharmaceuticals Inc.Updated: May 8, 2026Locations: 6
Eligibility criteria
Have histologically-confirmed unresectable, locally advanced, or metastatic sele... [+3]
Received treatment with another RBM39 degrader [+1]